Study of an experimental malaria vaccine in babies in Burkina Faso
Treatments studied
Part of Infections clinical trials.
This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby is 5 to 17 months old at the first vaccination
- A parent or guardian must agree in writing (or thumb-print) to join and follow the study
- Family lives in the study area and can come for all vaccinations and visits for 12 months after the last dose
- Baby does not have serious health problems (the study team will check heart/lung/stomach/nerve/liver/kidney and other major conditions)
- Baby should not have severe malnutrition or very low weight for age
- Baby must not have certain allergies to vaccines or history of serious allergic reactions (like anaphylaxis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults living in Burkina Faso. If you qualify, the vaccine is given to see if it can protect you from malaria.
This trial tests if adding a malaria vaccine to seasonal preventive medicines helps protect young children better from malaria. It is for healthy children living in certain areas of Burkina Faso and Mali.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.